Skip to content

Specificity Study of Diagnostic for Early Detection of Dengue Infection

Determination of Estimated Specificity of DENV Detect NS1 ELISAs

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02107677
Enrollment
300
Registered
2014-04-08
Start date
2012-08-31
Completion date
2014-08-31
Last updated
2017-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Diseases

Brief summary

This study assesses the specificity of DENV Detect™ NS1 ELISA versus standard reference tests (e.g. PCR or viral culture) for dengue diagnosis in the US. DENV Detect™ NS1 ELISA serves as an aid in the clinical laboratory diagnosis of early stages of Dengue infection in patients with clinical symptoms consistent with Dengue infection. This test is intended to be used on sera obtained within the first 7 days of symptoms. DENV Detect™ NS1 ELISA and rapid test results (positive or negative) must be confirmed by testing with a reference standard test. This study will use archived, leftover human serum samples that have been sequentially collected from areas non-endemic for Dengue infection. Each specimen must have been collected within the first 7 days of symptoms, and must be accompanied by clinical data demonstrating that the individual had symptoms consistent with Dengue infection. The samples will have no personally identifiable information. ELISAs and reference tests will be performed by different operators who are laboratory staff members. These staff members, blinded to each other's results, will evaluate the samples from each method independently.

Interventions

None listed

Sponsors

InBios International, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All age groups and both sexes. * Serum samples collected within 1- 7 days of onset of symptoms consistent with Dengue virus infection. * Information must be available about symptoms, age, and sex of patients from which samples are collected.

Exclusion criteria

* Any sample(s) with linked personal identifiers or any sample for which personal information can be discovered will be excluded.

Design outcomes

Primary

MeasureTime frame
number of subjects with negative resultone day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026